echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Nature: brain tumor deterioration accompanied by neural network remodeling

    Nature: brain tumor deterioration accompanied by neural network remodeling

    • Last Update: 2020-01-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    January 31, 2020 / Biovalley / recently, scientists from Baylor Medical College discovered a new mechanism of glioma deterioration: it accelerated the vicious circle by changing the activity of peripheral neurons, and promoted the development of epilepsy related to tumor deterioration Their findings, published in nature, suggest that mutations in the PIK3CA gene drive tumor progression, two of which significantly alter the expression of synaptic related genes in neurons The initial goal of the study was to develop an experimental system that would allow researchers to identify new cancer genes in mouse models of brain tumors In order to achieve this goal, Dr deneen laboratory and Dr Kenneth L Scott began to cooperate Based on the mouse model of glioma, they established a novel high-throughput screening platform to identify these PIK3CA variants Later, the researchers found a variety of mutations in the PIK3CA that drive glioma development Two of the PIK3CA mutations, c420r and h1047r, respectively, significantly drive tumor development In addition, some genes specifically expressed in glioma with c420r and h1047r gene mutations are involved in synaptic formation, which indicates that these tumor cells may affect synaptic formation of adjacent neurons "Because the above mutations of PIK3CA lead to different conformations of its proteins, these mutations may drive the development of glioma through different mechanisms." To study these different mechanisms, denien and his colleagues focused on synaptic genetic markers, says denien "It is well known that the destruction of synaptic structure will lead to changes in the connectivity and activity of neural networks, and in some cases, lead to seizures." Their research shows that c420r and h1047r mutations, which lead to the deterioration of glioma, do promote the excitability of neurons around the tumor, and reshape the neural network by inducing synapse formation Mice with these tumors had seizures much earlier than mice with other PIK3CA mutations The researchers studied the mechanism of c420r and h1047r glioma on their microenvironment, and found that these glioma can secrete several molecules of the glycocan (GPC) family, in which GPC3 protein drives the effect of hyperactivity and synaptic remodeling In addition, they found that GPC3 itself drives glioma formation These findings provide strong evidence for the influence of glioma on neuronal microenvironment for the first time Origin of information: brain tumors remote neural synapses to promote growth origin: PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis, nature (2020) Doi: 10.1038/s41586-020-1952-2
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.